A study of the tumour proliferation marker TPS in prostate cancer has been carried out.
The levels of this marker were determined in the following groups: controls (n = 51), prostate hyperplasia (n = 17), prostate cancer in clinical remission (n = 15), and progressive prostate cancer (n = 13). An upper normal limit of 129 U/l (percentile 95) was established.
When the progressive disease group was compared with the other groups, a significant difference (p < 0.001) was found. Sensitivity, specificity and positive predictive value obtained in order to dismiss progression were 71%, 94% and 62% respectively.
CITATION Actas Urol Esp. 1995 Feb;19(2):131-3
you maybe interested
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.